Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
Garey and Eubank, from the University of Houston School of Pharmacy, presented a scientific poster showing that in ... the treatment of MRSA, VRE and Anthrax infections. In March 2025, we ...
Q4 2024 Earnings Call Transcript March 18, 2025 Operator: Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter ...
Garey and Eubank from the University of Houston School of Pharmacy presented a scientific poster showing that in ... targeting the treatment of MRSA, VRE and Anthrax infections.
Acurx Pharmaceuticals reported its fourth-quarter 2024 earnings, delivering a narrower-than-expected loss per share. The company posted an EPS of -0.16, surpassing the forecast of -0.18.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback